fashion -WSS

fashion

author：comprehensive 2025-09-28 21:05:13 - browse：513

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

leisure time

WSS

Apple Watch's A

Telehealth startups turn to complex chronic diseases

STAT Virtual Event: Putting AI to the Test

STAT Virtual Event: Putting AI to the Test

Bird flu outbreak in cows is latest avian flu curveball

Second xenotransplant done with gene

entertainment

fashion

focus

Novavax promises a turnaround & Lilly roils the obesity market

H5N1 communication has been strictly for the birds

23andMe had bad news about my health. I wish a person had delivered it

What nurses really want: sufficient staffing for patient care

Trump demands the U.S. pay no more for drugs than other countries … again

Changes to biosimilar regulatory framework must prioritize patients

BioMarin wins approval for gene therapy to treat hemophilia A

It's been 20 years since Dolly the sheep. Where's my clone?

What does generative AI mean for health care? We asked experts

Microbiome research is starting to find links to chronic diseases

hotspot

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Dairy farmers resist CDC push for PPE against bird flu virus

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Sanofi strikes deal with Novavax, boosting the vaccine maker

Bird flu outbreak in cows is latest avian flu curveball

Study: Adult vaccinations pay for themselves in societal benefits

focus

leisure time

focus

entertainment